Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1992 Feb;33(2):143–148. doi: 10.1111/j.1365-2125.1992.tb04016.x

The disposition of oral and intramuscular pyrimethamine/sulphadoxine in Kenyan children with high parasitaemia but clinically non-severe falciparum malaria.

P A Winstanley 1, W M Watkins 1, C R Newton 1, C Nevill 1, E Mberu 1, P A Warn 1, C M Waruiru 1, I N Mwangi 1, D A Warrell 1, K Marsh 1
PMCID: PMC1381299  PMID: 1550695

Abstract

1. H.p.l.c. methods are described for the measurement of pyrimethamine and sulphadoxine in small volumes of plasma dried on filter paper strips. 2. Pyrimethamine/sulphadoxine (Fansidar, Hoffman LaRoche) was given by mouth and by intramuscular injection to children with uncomplicated falciparum malaria but with high parasitaemia (n = 8 for both routes; pyrimethamine 1.25 mg kg-1, sulphadoxine 25 mg kg-1). 3. Plasma concentrations of pyrimethamine and sulphadoxine associated with synergistic effects against pyrimethamine-resistant strains of Plasmodium falciparum in vitro were achieved within 1 h of administration and were maintained beyond the end of sampling. 4. After both oral and parenteral administration the plasma concentrations of both compounds were lower than those predicted by data from healthy subjects. 5. Areas under the plasma concentration-time curves of sulphadoxine after oral and i.m. administration did not differ significantly, although maximum plasma drug concentrations were higher after the i.m. route (P = 0.03). 6. The AUC values of pyrimethamine did not differ significantly between the two routes of administration. However, after i.m. administration AUC(0,24 h) values were smaller (P = 0.03), and the time to maximum plasma drug concentration (tmax) was longer (P = 0.004) than when the drug was given orally.

Full text

PDF
143

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berenbaum M. C. A method for testing for synergy with any number of agents. J Infect Dis. 1978 Feb;137(2):122–130. doi: 10.1093/infdis/137.2.122. [DOI] [PubMed] [Google Scholar]
  2. Brandling-Bennett A. D., Oloo A. J., Watkins W. M., Boriga D. A., Kariuki D. M., Collins W. E. Chloroquine treatment of falciparum malaria in an area of Kenya of intermediate chloroquine resistance. Trans R Soc Trop Med Hyg. 1988;82(6):833–837. doi: 10.1016/0035-9203(88)90009-0. [DOI] [PubMed] [Google Scholar]
  3. Chulay J. D., Watkins W. M., Sixsmith D. G. Synergistic antimalarial activity of pyrimethamine and sulfadoxine against Plasmodium falciparum in vitro. Am J Trop Med Hyg. 1984 May;33(3):325–330. doi: 10.4269/ajtmh.1984.33.325. [DOI] [PubMed] [Google Scholar]
  4. Edstein M. D. Pharmacokinetics of sulfadoxine and pyrimethamine after Fansidar administration in man. Chemotherapy. 1987;33(4):229–233. doi: 10.1159/000238499. [DOI] [PubMed] [Google Scholar]
  5. Gubler J. Sulfadoxine-pyrimethamine resistant malaria from west or central Africa. Br Med J (Clin Res Ed) 1988 Feb 6;296(6619):433–433. doi: 10.1136/bmj.296.6619.433-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Harinasuta T., Viravan C., Buranasin P. Parenteral Fansidar in falciparum malaria. Trans R Soc Trop Med Hyg. 1988;82(5):694–694. doi: 10.1016/0035-9203(88)90203-9. [DOI] [PubMed] [Google Scholar]
  7. Hellgren U., Angel V. H., Bergqvist Y., Arvidsson A., Forero-Gomez J. S., Rombo L. Plasma concentrations of sulfadoxine-pyrimethamine and of mefloquine during regular long term malaria prophylaxis. Trans R Soc Trop Med Hyg. 1990 Jan-Feb;84(1):46–49. doi: 10.1016/0035-9203(90)90376-p. [DOI] [PubMed] [Google Scholar]
  8. Hellgren U., Kihamia C. M., Bergqvist Y., Lebbad M., Premji Z., Rombo L. Standard and reduced doses of sulfadoxine-pyrimethamine for treatment of Plasmodium falciparum in Tanzania, with determination of drug concentrations and susceptibility in vitro. Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):469–472. doi: 10.1016/0035-9203(90)90002-v. [DOI] [PubMed] [Google Scholar]
  9. Keuter M., van Eijk A., Hoogstrate M., Raasveld M., van de Ree M., Ngwawe W. A., Watkins W. M., Were J. B., Brandling-Bennett A. D. Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya. BMJ. 1990 Sep 8;301(6750):466–470. doi: 10.1136/bmj.301.6750.466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Lege-Oguntoye L., Adagu S. I., Werblinska B., Ogala W. N., Slotboom A. B. Resistance of Plasmodium falciparum to sulfadoxine-pyrimethamine combination in semi-immune children in Zaria, northern Nigeria. Trans R Soc Trop Med Hyg. 1990 Jul-Aug;84(4):505–506. doi: 10.1016/0035-9203(90)90016-8. [DOI] [PubMed] [Google Scholar]
  11. Nevill C. G., Watkins W. M. Efficacy of pyrimethamine/sulfadoxine in uncomplicated severe falciparum malaria in Kenya. Lancet. 1990 Jul 21;336(8708):185–185. doi: 10.1016/0140-6736(90)91713-k. [DOI] [PubMed] [Google Scholar]
  12. Niang I., Senghor A. S., Sanokho A. Utilisation du Fansidar injectable dans le paludisme de l'enfant à Dakar. Bull Soc Med Afr Noire Lang Fr. 1975;20(1):15–19. [PubMed] [Google Scholar]
  13. Phillips R. E., Warrell D. A., Edwards G., Galagedera Y., Theakston R. D., Abeysekera D. T., Dissanayaka P. Divided dose intramuscular regimen and single dose subcutaneous regimen for chloroquine: plasma concentrations and toxicity in patients with malaria. Br Med J (Clin Res Ed) 1986 Jul 5;293(6538):13–16. doi: 10.1136/bmj.293.6538.13. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Salako L. A., Adio R. A., Sowunmi A., Walker O. Parenteral sulphadoxine-pyrimethamine (Fansidar): an effective and safe but under-used method of anti-malarial treatment. Trans R Soc Trop Med Hyg. 1990 Sep-Oct;84(5):641–643. doi: 10.1016/0035-9203(90)90131-w. [DOI] [PubMed] [Google Scholar]
  15. Schapira A., Bygbjerg I. C., Jepsen S., Flachs H., Bentzon M. W. The susceptibility of Plasmodium falciparum to sulfadoxine and pyrimethamine: correlation of in vivo and in vitro results. Am J Trop Med Hyg. 1986 Mar;35(2):239–245. doi: 10.4269/ajtmh.1986.35.239. [DOI] [PubMed] [Google Scholar]
  16. Shenton F. C., Bots M., Menon A., Eggelte T. A., de Wit M., Greenwood B. M. An ELISA test for detecting chloroquine in urine. Trans R Soc Trop Med Hyg. 1988;82(2):216–220. doi: 10.1016/0035-9203(88)90415-4. [DOI] [PubMed] [Google Scholar]
  17. Timmermanns P. M., Hess U., Jones M. E. Pyrimethamine/sulfadoxine resistant falciparum malaria in East Africa. Lancet. 1982 May 22;1(8282):1181–1181. doi: 10.1016/s0140-6736(82)92243-7. [DOI] [PubMed] [Google Scholar]
  18. Watkins W. M., Percy M., Crampton J. M., Ward S., Koech D., Howells R. E. The changing response of Plasmodium falciparum to antimalarial drugs in east Africa. Trans R Soc Trop Med Hyg. 1988;82(1):21–26. doi: 10.1016/0035-9203(88)90250-7. [DOI] [PubMed] [Google Scholar]
  19. Weidekamm E., Plozza-Nottebrock H., Forgo I., Dubach U. C. Plasma concentrations in pyrimethamine and sulfadoxine and evaluation of pharmacokinetic data by computerized curve fitting. Bull World Health Organ. 1982;60(1):115–122. [PMC free article] [PubMed] [Google Scholar]
  20. White N. J., Krishna S. Treatment of malaria: some considerations and limitations of the current methods of assessment. Trans R Soc Trop Med Hyg. 1989 Nov-Dec;83(6):767–777. doi: 10.1016/0035-9203(89)90322-2. [DOI] [PubMed] [Google Scholar]
  21. White N. J., Krishna S., Waller D., Craddock C., Kwiatkowski D., Brewster D. Open comparison of intramuscular chloroquine and quinine in children with severe chloroquine-sensitive falciparum malaria. Lancet. 1989 Dec 2;2(8675):1313–1316. doi: 10.1016/s0140-6736(89)91918-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES